title: Musculoskeletal complications of neutron therapy for prostate cancer.
abstract: The purpose of this study was to investigate the cause of hip complaints following conformal neutron therapy delivered by opposed lateral and oblique anterior ports to treat prostate cancer. Twenty-seven patients with hip complaints following neutron or mixed neutron and photon therapy for prostate cancer had 34 magnetic resonance imaging (MRI) studies 3-39 (mean 15.3) months following treatment; for comparison, 13 similarly treated patients without hip complaints were imaged 1-32 (mean 13.8) months post-treatment; 25/40 imaged patients received concurrent nonsteroidal hormone therapy. Coronal and axial images of the hips/pelvis were obtained utilizing T1 weighted spin echo and fat suppressed inversion recovery (STIR) sequences. Signal amplitude (SA) of involved muscles was measured on the STIR images and normalized to that of the psoas outside the treatment field. Hip complaints ranged from mild soreness or motion limitation to severe pain and limitation of ambulation; presence and severity of symptoms (sx) were significantly related to neutron dose (P = 0.020 and 0.0001) but not to hormone therapy (each P > 0.17). Normalized SA of the obturator muscles differed significantly with neutron dose (P = 0.013), the presence, and the severity, of sx (P = 0.0002 and 0.0007); estimated extent of abnormal muscle also differed significantly with neutron dose (P = 0.039), presence, and severity, of sx (P = 0.00004 and 0.0007); [hormone treatment had a profound effect on SA (P = 0.0001) and extent (P = 0.005) which was independent of sx (P = 0.10 and 0.14, respectively) and neutron dose (P = 0.33 and 0.32, respectively)]. Subcutaneous changes localized lateral to the greater trochanter were seen in all, and edema of the subjacent gluteus muscles in many, symptomatic hips; only 4/13 asymptomatic hips showed subcutaneous changes, 6 had mild gluteus edema. Avascular necrosis of the femoral head was seen in 5 symptomatic hips, with marked acetabular necrosis in 3 of these; small joint effusions were seen in 8 symptomatic hips; asymptomatic hips had no significant bone or joint abnormalities. Neutron therapy for prostate cancer designed to spare the rectum results in significant dose-dependent, musculoskeletal complications which are well demonstrated by MRI. SA abnormalities of irradiated muscle correlate significantly with neutron dose and both presence and severity of hip sx. Protocol modifications have been implemented to reduce these complications. MRI provides an objective means to assess both complications and the success of new protocols in ameliorating them. Concurrent hormone therapy has a profound effect on muscle changes on MRI which is independent of neutron dose and sx.
authors.affiliation: Department of Radiology, Wayne State University, Detroit, Michigan 48201, USA. rsoulen@med.wayne.edu
authors.forename: R L
authors.initials: RL
authors.lastname: Soulen
authors.forename: J A
authors.initials: JA
authors.lastname: Romero
authors.forename: P J
authors.initials: PJ
authors.lastname: Chuba
authors.forename: J L
authors.initials: JL
authors.lastname: Evelhoch
authors.forename: R E
authors.initials: RE
authors.lastname: Simpson
authors.forename: J D
authors.initials: JD
authors.lastname: Forman
mesh_terms: D000273:Adipose Tissue / Q000473:pathology / Q000528:radiation effects; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004307:Dose-Response Relationship, Radiation; D005500:Follow-Up Studies; D006615:Hip / Q000473:pathology / Q000528:radiation effects; D006621:Hip Joint / Q000473:pathology / Q000528:radiation effects; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D018482:Muscle, Skeletal / Q000473:pathology / Q000528:radiation effects; D009140:Musculoskeletal Diseases / Q000175:diagnosis / Q000209:etiology*; D017247:Neutron Capture Therapy / Q000009:adverse effects*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000532:radiotherapy*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal